About 7 results found for searched term "SI-109" (0.304 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M21406 | SI-109 | STAT |
| SI-109 is a potent STAT3 SH2 domain structural domain inhibitor (Ki=9 nM) with antitumor activity. si-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). si-109 and the CRBN analogue lenalidomide ligand were used to design the PROTAC STAT3 degradation agent SD- 36. | ||
| M54645 | SION-109 | CFTR |
| SION-109 is a transmembrane conductance regulator (CFTR) modulator that targets the interface of CFTR nucleotide-binding domain 1 (NBD1) interaction with the CFTR intracellular loop 4 (ICL4) protein domain. | ||
| M9490 | YL-109 | Aryl hydrocarbon Receptor |
| YL-109 is a novel anticancer agent, which can inhibit breast cancer cell growth and invasiveness in vitro and in vivo, YL-109 is also an STUB1 enhancer. | ||
| M11496 | FGF-basic, Rat (E. coli) | Recombinant Proteins |
| Fibroblast Growth Factor-basic; FGF-2; BFGF; FGFB; HBGF-2; bFGF; Prostatropin | ||
| FGF-basic, Rat（E. coli） Expressed with an n-terminal Gly. FGF-basic (Pro10-Ser154) Accession # P13109. Bioactivity: ED50 < 0.25 ng/ mL, measured by 3T3 cell proliferation method, corresponding to > 4.0 × 106 units /mg. | ||
| M21159 | SD-36 | PROTAC |
| SD-36 is a potent STAT3 PROTAC degradation agent (Kd=~50 nM) with a high selectivity compared to other STAT members. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase. | ||
| M25132 | Casirivimab | Anti-infection |
| REGN10933 | ||
| Casirivimab (REGN10933) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Casirivimab lacks efficacy against COVID-19 variants. Casirivimab can be used in combination with Imdevimab , it reduces viral load and improves diseases. | ||
| M40637 | TD-1092 | IAP |
| TD-1092 is a pan-inhibitor of apoptosis (IAP) degrader with two different types of E3 ligase conjugates, IAP and CRBN, that induces proteasomal degradation of cIAP2 and XIAP in a CRBN-dependent manner. TD1092 also activates apoptotic proteases (apoptosis 3/7) and leads to apoptosis by promoting IAP degradation. In addition, TD1092 also blocks the TNFα-mediated NF-κB signaling pathway and inhibits the phosphorylation of IKK, IkBα, p65, and p38. TD1092 can be used as a PROTAC for cancer research. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
